Russell Investments Group Ltd. Has $55.97 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Russell Investments Group Ltd. grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 81.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 650,663 shares of the company's stock after buying an additional 291,524 shares during the quarter. Russell Investments Group Ltd.'s holdings in Novo Nordisk A/S were worth $55,970,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in NVO. Optimist Retirement Group LLC lifted its holdings in shares of Novo Nordisk A/S by 4.3% in the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company's stock valued at $327,000 after buying an additional 112 shares during the period. M. Kulyk & Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares during the last quarter. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the last quarter. Tradewinds Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 2.6% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after buying an additional 124 shares during the period. Finally, Exencial Wealth Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Remove Ads

Novo Nordisk A/S Stock Down 7.0 %

Shares of NVO stock traded down $4.57 during trading on Thursday, hitting $60.52. 5,959,808 shares of the company were exchanged, compared to its average volume of 5,741,755. Novo Nordisk A/S has a twelve month low of $59.37 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a market capitalization of $271.59 billion, a price-to-earnings ratio of 18.32, a P/E/G ratio of 0.90 and a beta of 0.61. The business's 50-day simple moving average is $78.66 and its 200 day simple moving average is $94.43.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is currently 49.54%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NVO. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Monday. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.